Merck Stresses Overall Survival In Keytruda/Chemo '189 Trial Revamp

Merck is changing the statistical analysis of combination study in first-line lung cancer to include dual endpoints of progression-free-survival and overall survival, and has withdrawn a filing for the combination in Europe based on mid-stage data.